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Sudden cardiac death (SCD) is a rare but devastating complication of a number of underlying cardio-
vascular diseases. While coronary artery disease and acute myocardial infarction are the most common
causes of SCD in older populations, inherited cardiac disorders comprise a substantial proportion of SCD
cases aged less than 40 years. Inherited cardiac disorders include primary inherited arrhythmogenic
disorders such as familial long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic poly-
morphic ventricular tachycardia (CPVT), and inherited cardiomyopathies, most commonly hypertrophic
cardiomyopathy (HCM). In up to 40% of young SCD victims (deﬁned as 1–40 years old, excluding sudden
unexplained death in infancy from 0 to 1 years, referred to as SIDS), no cause of death is identiﬁed at
postmortem [so-called “autopsy negative” or “sudden arrhythmic death syndrome” (SADS)]. Manage-
ment of families following a SCD includes the identiﬁcation of the cause of death, based either on pre-
morbid clinical details or the pathological ﬁndings at the postmortem. When no cause of death is
identiﬁed, genetic testing of DNA extracted from postmortem tissue (the molecular autopsy) may
identify a cause of death in up to 30% of SADS cases. Targeted clinical testing in a specialized multi-
disciplinary clinic in surviving family members combined with the results from genetic testing, provide
the optimal setting for the identiﬁcation of relatives who may be at risk of having the same inherited
heart disease and are therefore also predisposed to an increased risk of SCD.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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Semsarian).1. Introduction
Sudden cardiac death (SCD) is a tragic complication of a num-
ber of cardiovascular diseases. The death can occur at all ages, andopen access article under the CC BY-NC-ND license
Table 1
Postmortem criteria for a “negative autopsy”.
 Structurally normal heart
 No abnormal histopathological ﬁndings in the heart
 No other cause of death identiﬁed at postmortem (e.g. pulmonary embolus
or cerebral aneurysm)
 Normal blood toxicology screen
 No pre-death clinical features to suggest other causes of sudden death (e.g.
epilepsy or asthma)
C. Semsarian, J. Ingles / Journal of Arrhythmia 32 (2016) 359–365360in the young it is often unexpected when it occurs in a previously
healthy and asymptomatic person [1–3]. SCD is deﬁned as a death
occurring within an hour of the onset of symptoms, due to an
underlying cardiac disease. The prevalence of SCD is signiﬁcant,
with at least 3 million people worldwide dying suddenly each year.
In the United States, SCD occurs in up to 450,000 people each year,
translating to over 1000 deaths per day, or one SCD every 1.5 min
[2,4].
SCD is signiﬁcantly more common in older age groups, and the
incidence in young people aged less than 40 years is generally low.
The best estimate of the incidence of SCD in the general popula-
tion aged 20–75 years is 1 in every 1000 individuals, accounting
for 18.5% of all deaths [5]. In the 1–40 age group, the incidence is
up to 8.5 per 100,000 person years, including competitive athletes
[4–9]. While relatively uncommon, the SCD of a young person is a
devastating event. In addition, the public health burden of pre-
mature death for men and women is greater for SCD than for all
individual cancers and most other leading causes of death [10].2. Causes of sudden cardiac death in the young
The causes of SCD can be broadly divided into structural and
arrhythmogenic etiologies. In subjects over the age of 40 years,
coronary artery disease and acute myocardial infarction account
for over 90% of SCD cases [2,11]. Fig. 1 summarizes the causes of
SCD in the young (aged 0–40), illustrating the lower prevalence of
coronary artery disease and higher proportion of inherited heart
diseases. Structural causes of SCD in the young include inherited
cardiomyopathies, such as hypertrophic cardiomyopathy (HCM),
dilated and restrictive cardiomyopathies, arrhythmogenic right
ventricular cardiomyopathy (ARVC), and left ventricular non-
compaction. Other structural causes of SCD in the young include
myocarditis, congenital heart diseases, and coronary artery disease
[12,13]. HCM is the most common inherited heart disease with a
prevalence of 1 in every 200 people [14]. HCM remains the most
common structural cause of SCD in the young, including compe-
titive athletes [15]. Of note, in all structural causes of SCD in the
young, the postmortem examination has a high probability of
identifying the cause of death.
The main inherited arrhythmogenic causes of SCD in the young
are summarized in Fig. 1. These arrhythmogenic disorders include
familial long QT syndrome (LQTS), catecholaminergic polymorphic
ventricular tachycardia (CPVT), Brugada syndrome (BrS), idio-
pathic ventricular ﬁbrillation, early repolarization syndromes, and
short QT syndrome. Since these disorders rarely cause any struc-
tural changes to the heart, the postmortem is often “negative” (noSudden Cardiac Death 
(0-40 years) 
Coronary  
Artery Disease 
Cause identified  
(~60%)
No cause identified  
i.e. SADS (~40%)
Myocarditis 
HCM ARVC LQTS CPVT Others Others 
Others Structural  
Heart Disease
Arrhythmogenic 
Disease
Fig. 1. Causes of sudden cardiac death in the young (0–40 years) based on post-
mortem ﬁndings. SADS¼sudden arrhythmic death syndrome, LQTS¼ long QT
syndrome, CPVT1¼catecholaminergic polymorphic ventricular tachycardia type 1,
HCM¼hypertrophic cardiomyopathy, ARVC¼arrhythmogenic right ventricular
cardiomyopathy.cause of death is identiﬁed), including normal histopathology and
toxicology analyses (key features are summarized in Table 1). Such
cases in which no abnormalities are found at the postmortem
examination occur in up to 40% of SCD cases in young populations
[7,8,12,16–18]. This strongly suggests an underlying arrhythmo-
genic cause (Fig. 1). Sudden unexplained deaths are often referred
to as sudden arrhythmic death syndrome (SADS) with “young”
deﬁned as 1–40 years old (excluding sudden unexplained death in
infancy from 0 to 1 years, referred to as SIDS) [19]. The true overall
incidence of SCD is likely to be an underestimate, since primary
arrhythmogenic disorders can predispose people to more overt
causes of death, such as drowning and motor vehicle accidents.
Such overt causes may be caused by ventricular arrhythmias in
patients with LQTS and CPVT [20–22].3. Role of the postmortem in the investigation of sudden
cardiac death in the young
Establishing a deﬁnitive cause of death in a young SCD case is of
major importance, and so the postmortem evaluation is a critical
ﬁrst step in all cases (Fig. 2). Important aspects of the postmortem
include the proper and detailed conduct of the postmortem
examination itself, collection of appropriate samples for sub-
sequent analysis (including DNA analysis), careful evaluation of
the ﬁndings, and a precise and accurate ﬁnal conclusion are
important aspects of the role of the postmortem. A comprehensive
and detailed postmortem process can not only deﬁne the exact
cause of death in a young SCD case, but the results also have far-
reaching effects in identifying at-risk relatives of the decedent.
This information can thereby provide a therapeutic window for
disease and sudden death prevention in at-risk relatives (Fig. 2).
The key aspects of the postmortem evaluation are summarized
in Table 2, and are modiﬁed from the Best Practice Guidelines of the
Royal Australasian College of Pathologists implemented in Australia
in 2008 [23]. A comprehensive postmortem by an experienced
forensic pathologist should be performed in all SCD cases in the
young (0–40 years) [19,23,24]. A complete premorbid medical
history should be sought, including a history of syncopal episodes,
exertional symptoms, intercurrent illnesses, recent pharmacolo-
gical therapies, previous ECGs, and other relevant studies. The
investigation should also include a comprehensive, 3-generation
family pedigree focused on identifying any family history of car-
diac disease, premature sudden death, or suspicious deaths (e.g.
SIDS cases or drowning). Other relevant family history information
can include family members with epilepsy, identifying “fainters”,
and any other unusual symptoms or clinical presentations. The
circumstances of SCD need to be established when possible,
including activity at the time of death, the level of physical activity,
and the symptoms immediately preceding the death. This often
relies on obtaining information from available ambulance and
police reports, as well as talking to witnesses or those who found
the deceased.
The postmortem examination should include a detailed macro-
scopic and histological evaluation of the heart, as well as other
key organs such as the brain, with the purpose of identifying any
Postmortem Examination Process 
Premorbid & family history 
Circumstances of death 
Pathology & microscopy 
Collection of Blood 
For future genetic analysis 
Cause of Sudden Cardiac Death 
For future genetic analysis 
Inform and Refer Family 
tnatropmiylimafhtiwnosiailesolC
Clinical Evaluation of Family 
Multidisciplinary specialized clinic 
Ion channelopathy genes, other 
Management of Family 
Diagnosis, treatment, prevention strategies 
Fig. 2. Evaluation of families in the setting of a sudden cardiac death in a young
family member. Genetic testing is often performed concurrently with clinical
evaluation of family members. This ﬁgure is modiﬁed from Semsarian et al. [34].
Table 2
Key aspects of the postmortem process in SCD cases.
 Performed in all cases of sudden unexplained death in the young (0–40
years)
 Detailed premorbid clinical history
 Comprehensive family history
 Skilled macroscopic and microscopic examination of all organs, particularly
the heart and brain
 Adequate collection of histological material for review or referral if
necessary
 Collection of 5–10 mL of whole blood, and frozen sections of highly cellular
tissues (e.g. liver or spleen), where possible, for future DNA extraction and
analysis
 Early liaison with a multidisciplinary specialized cardiac genetics service
C. Semsarian, J. Ingles / Journal of Arrhythmia 32 (2016) 359–365 361non-cardiac causes of death (e.g. pulmonary embolism or cerebral
aneurysm), before focusing on speciﬁc cardiac pathologies. In all SCD
cases in the young, a 5–10mL blood sample should be collected for
subsequent DNA extraction and analysis. In addition, frozen sections
of the liver or spleen, which are highly cellular and therefore rich in
DNA, should also be collected and stored when possible. Of note,
parafﬁn-embedded tissues are not suitable for DNA studies, as the
quality of the DNA is signiﬁcantly diminished [25,26]. Obtaining a
postmortem blood sample in young SCD cases is now recommended
by the HRS/EHRA guidelines [24], and is mandated in several coun-
tries, including Australia and New Zealand [23]. A representative best
practice document entitled “Postmortem in sudden unexpected death inthe young: guidelines on autopsy practice” and endorsed by the Royal
College of Pathologists of Australasia is detailed in Supplementary File 1.
Despite our best efforts, the cause of SCD in young individuals
is sometimes not established; no cause is identiﬁed in up to 40% of
cases. Importantly, whether a cause of death is established or not,
the possibility of an underlying inherited cardiac disorder remains
in many cases, including the possibility of a primary arrhythmo-
genic disease. Recent studies also suggest that in addition to true
SADS cases, postmortem examinations may reveal some non-
speciﬁc changes of uncertain clinical signiﬁcance, such as unclas-
siﬁed “cardiomegaly” or minor cardiac histopathological changes.
Importantly, the chance of ﬁnding an underlying primary
arrhythmogenic syndrome in these uncertain “borderline” cases is
as high as in those with true SADS [27].
While the conventional postmortem remains the cornerstone
of the investigation of young SCD cases, there is emerging evi-
dence that other imaging modalities may be helpful in diagnosing
structural causes of SCD. Such non-invasive approaches may
overcome some of the reservations that families have in pro-
ceeding with the traditional postmortem process for religious,
logistic, personal, or cultural reasons. These modalities include
computer tomography (CT) scanning and cardiovascular magnetic
resonance (CMR) imaging [28]. The majority of the studies to date
examining the accuracy of postmortem CMR imaging have focused
on fetal and neonatal deaths [29,30]. Two recent studies have
shown great promise in terms of utilizing CT and CMR imaging in
determining the cause of SCD in young adults [31,32]. Fig. 3 shows
young SCD cases in which postmortem imaging identiﬁed the
causes of death due to ARVC, HCM, and acute coronary occlusion
[32]. While the studies represent a small number of young SCD
cases, the possibility of additional diagnostic tools to elucidate the
cause of SCD at the postmortem now exists.4. Genetic testing and the “molecular autopsy”
The use of genetic testing in the setting of SCD cases was
initiated over a decade ago [33]. In SADS, where no cause of death
is identiﬁed after a comprehensive postmortem examination,
genetic testing of the decedent’s blood sample collected at post-
mortem may identify an underlying genetic cause of sudden death.
This genetic testing process has been termed the “molecular
autopsy”, and involves DNA extraction from postmortem blood,
followed by DNA analysis of selected candidate genes responsible
for the main inherited arrhythmogenic diseases (Fig. 4) [34,35].4.1. The traditional “molecular autopsy”
The traditional molecular autopsy has focused on direct DNA
sequencing of the protein coding exons of 4 genes, including the
three major LQTS genes (KCNQ1, KCNH2, SCN5A) and the CPVT
gene (RYR2, Table 3) [24,36,37]. Mutations in the SCN5A gene cause
LQTS3 and also BrS. Initial studies in highly-selected SADS popu-
lations reported detection rates for a disease-causing (pathogenic)
mutation of up to 34% [33,38]. However, more recent studies
suggest the detection rate with the 4-gene molecular autopsy is
more likely to be up to 15–20% [39] (Table 3), ranging from 0% to
35% [25,33,39–44]. This largely reﬂects a range of clinical and
methodological issues relating to the type of DNA obtained,
selection bias of the populations studied, the deﬁnition of sudden
death, and variation in the stringency and interpretation of DNA
variants in terms of pathogenicity.
Fig. 3. Role of CT scanning and cardiac magnetic resonance imaging postmortem. Diagnosis of arrhythmogenic right ventricular cardiomyopathy (A, B), hypertrophic
cardiomyopathy (C, D), acute coronary occlusion, and myocardial infarction (E, F) based on histological and imaging analyses. This ﬁgure was modiﬁed from Puranik et al.
[32].
C. Semsarian, J. Ingles / Journal of Arrhythmia 32 (2016) 359–3653624.2. The “exome-wide molecular autopsy”
Recent advances in next generation sequencing technologies
have allowed ever expanding panels of genes (cardiac gene panels
with up to 200 genes) to be re-sequenced from comparatively
small quantities of DNA, with excellent throughput capabilities,
and in a cost-efﬁcient manner. This includes sequencing the pro-
tein coding exons of all 22,000 genes (the “exome”). Next gen-
eration sequencing technologies thus offer the technology for an
“exome-wide molecular autopsy”, and potentially allow genetic
testing of all major disease-associated genes, as well as genes less
frequently involved in any given disease. We recently used an
exome-wide approach in a series of SADS cases in a proof-of-
principle study [42]. Using stringent pathogenicity criteria, a likelypathogenic variant was identiﬁed in 32% of cases. Moreover, the
exome data provided information on a number of gene variants
currently being evaluated for novel disease associations, and an
archive of genotypes that can be mined in the future as new SADS-
associated genes are characterized.
4.3. Determining pathogenicity of the identiﬁed genetic variants
The major Achilles’ heel of genetic testing and the molecular
autopsy is establishing genetic causality or pathogenicity. While
newer genetic technologies provide excitement and hope of
identifying more genetic causes of SCD in the young, the uncer-
tainty surrounding the pathogenicity of the identiﬁed genetic
variants is an important drawback to consider. In addition, the
Genetic analysis 
Sanger sequencing 
Cardiac gene panels 
Whole exome / genomes 
Fig. 4. Steps in the molecular autopsy process. DNA is extracted from blood collected at postmortem. Subsequent DNA analysis of selected genes is done by Sanger
sequencing or newer parallel next generation sequencing platforms. This ﬁgure was modiﬁed from Semsarian et al. [35].
Table 3
Current 4-gene molecular autopsy.
Gene name Encoded protein Disease % of disease % of SADSa
KCNQ1 IKs Kþ channel α-subunit LQTS1 35–40 10–15
KCNH2 IKr Kþ channel α-subunit LQTS2 30–35 1–5
SCN5A INa Naþ channel α-subunit LQTS3 5–10 o1
BrS 15–25 o1
RYR2 Ryanodine receptor CPVT1 60–65 10–20
LQTS¼ long QT syndrome, BrS¼Brugada syndrome, CPVT1¼catecholaminergic
polymorphic ventricular tachycardia type 1, SADS¼sudden arrhythmic death syn-
drome (normal postmortem).
a Pick-up rate for molecular autopsy.
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several variants may cumulatively contribute to disease [45] and
the inevitable clinical implications of incidental and secondary
ﬁndings [46] are all important considerations in the setting of the
molecular autopsy.
In brief, determining the pathogenicity of the variants identi-
ﬁed in the postmortem setting is complicated by the absence of a
true “phenotype” in the deceased. In general, many factors need to
be considered in determining pathogenicity including the type of
mutation, the frequency of the variation in genetic population
databases, the type of amino acid change and its conservation, the
predicted damaging effect using in silico tools, supportive func-
tional data, and evidence of co-segregation of the variant within a
family [46,47]. Taking such factors into account, the genetic variant
is classiﬁed as pathogenic (disease-causing), benign, or of uncer-
tain signiﬁcance [so-called “variant of uncertain signiﬁcance”
(VUS)] [46–49]. Generally speaking, pathogenic and likely patho-
genic variations can be used for cascade testing of surviving family
members, while a VUS and benign ﬁndings do not impact clinical
care [46]. The key consideration for the clinician seeing the sur-
viving family of the decedent is that cardiac genetic results are
“probabilistic.” As such, they are on a gradation or continuum from
benign (clinically insigniﬁcant), to VUS (may become clinically
signiﬁcant), to pathogenic (clinically highly signiﬁcant). Impor-
tantly, genetic testing to determine the underlying genetic cause of
disease in a family is not a binary “yes/no” outcome. Therefore,efforts to gather evidence of causation are important, as variants
with little certainty of their pathogenicity could lead to potential
danger if used as a screening tool for the remaining family
members. The worst-case scenario would be releasing a family
member from clinical surveillance based on an incorrect gene
result. This is an important consideration in family management
and highlights the need to consider the genetic ﬁndings of the
molecular autopsy with caution, and in conjunction with clinical
ﬁndings derived from screening family relatives.
These complexities highlight both the need for ongoing colla-
borative efforts to improve the ways we determine pathogenicity
and the key role of the specialized multidisciplinary model of care
for SCD and families with genetic heart diseases [50]. This is
especially important and relevant in the setting of SADS, where
there is no phenotype in the decedent in up to 40% of cases.
Correlation between the pathogenicity of a genetic ﬁnding at the
molecular autopsy and the absence of a phenotype in the decedent
becomes very challenging. In this situation, we rely heavily on the
characteristics of the variant, rarity in populations, previous
reports, any available functional data, and overall predictions from
in silico tools. Finding a relevant clinical cardiac phenotype in
family relatives of the decedent may signiﬁcantly help in the
determination of pathogenicity of genetic variants identiﬁed in
young SADS cases.5. Management of families following sudden cardiac death in
the young
Given the possibility of an inherited cardiac disease as a cause
of SCD, appropriate evaluation and management of the surviving
family is essential. Overall clinical management is guided by the
goal of establishing a cause of death (the victim), and the clinical
screening and management of the surviving family members (the
family). The ultimate goal is prevention of SCD in any other family
relatives. In SADS cases, underpinning the clinical evaluation and
screening of family members is the presumption that the under-
lying cause was an inherited arrhythmogenic disorder such as
LQTS, CPVT, or BrS. By deﬁnition, these SCD cases are unexplained
at postmortem. Importantly however, over 95% of cardiac genetic
Specialized Multidisciplinary 
Inherited Heart Disease Clinic 
Initial Evaluation (Tier 1) 
Clinical & family history 
Physical examination 
Resting ECG 
Exercise ECG 
Echocardiogram 
Other Investigations (Tier 2) 
CMR imaging 
24 hour ambulatory ECG 
SAECG 
Pharmacological challenge* 
Diagnosis? Molecular Autopsy 
Findings 
YES 
Manage according to 
underlying diagnosis 
NO 
Appropriate follow-up 
based on age, symptoms 
Fig. 5. Clinical investigation pathway of surviving family members when no cause
of death is identiﬁed. CMR¼cardiac magnetic resonance, ECG¼electrocardiogram,
SAECG¼signal averaged ECG. This ﬁgure was modiﬁed from Priori et al. [19].
Sudden Death  
Family 
Cardiologists
Geneticist 
Forensic 
Pathologist 
Genetic 
Counsellor
Gene Testing 
Centres 
Research  
Centres 
Patient Support 
Groups 
Nurse, PCP, 
Psychologist 
Fig. 6. Specialized multidisciplinary approach to caring for families with a sudden
cardiac death in a young family member. PCP¼primary care physician. This ﬁgure
was modiﬁed from Ingles et al. [59].
C. Semsarian, J. Ingles / Journal of Arrhythmia 32 (2016) 359–365364disorders are inherited as an autosomal dominant trait such that
ﬁrst-degree relatives have a 1 in 2 (50%) chance of inheriting the
same gene mutation [36,37]. Therefore, standard approaches for
clinical evaluation of ﬁrst-degree relatives are important, and may
reveal disease in the family.
Fig. 5 summarizes the basic clinical investigation of the family,
including ﬁrst-degree relatives, obligate carriers, and symptomatic
relatives. This is largely based on the recent HRS/EHRA consensus
document [19]. Clinical investigation broadly involves two tiers of
evaluation. All relatives should have a comprehensive medical and
family history, physical examination, resting and exercise ECGs,
and a standard transthoracic echocardiogram. Depending on the
clinical situation, further second tier investigations may include
CMR imaging, 24-h ECG monitoring and signal averaged ECG, and
pharmacological challenge tests, such as an ajmaline challenge in
suspected BrS patients. Clinical evaluation alone in families with a
sudden unexplained death may identify an underlying cause in up
to 50% of selected and comprehensively evaluated families in
tertiary centers [51–53].
Concurrent with the clinical evaluation of the family, the
genetic ﬁndings from a molecular autopsy may help to elucidate
the cause of death in the decedent, as well as provide a basis for
cascade genetic testing of at-risk family members. Offering cas-
cade genetic testing to asymptomatic relatives should always be
performed in conjunction with clinical evaluation, and only
alongside comprehensive pre- and post-test genetic counseling
[47]. Cascade genetic testing may also reveal de novo cases, where
the parents of the decedent do not carry the disease-causing
mutation. In this case, the only at-risk relatives would be the
offspring of the decedent.
If an underlying diagnosis is made using both clinical and
genetic evaluation of the family, subsequent management and
follow-up depend on the disease in question. This will often trig-
ger more speciﬁc family cascade clinical screening, and, if avail-
able, genetic testing [24]. If no diagnosis is made after a compre-
hensive clinical (7genetic) review, then asymptomatic adult
relatives can be discharged from care on the proviso that new
symptoms or family information should be reported immediately.
More commonly, the relative being screened is a child, in which
case regular follow-up is indicated until adulthood, with the
knowledge that many genetic heart diseases most commonlymanifest as clinical disease in the second decade of life [54,55].
Some diseases such as ARVC or HCM may occasionally present
later in life; the clinical follow-up duration may therefore need to
be extended.
Family management in the setting of SCD of a young person is
complex and ideally suited for a multidisciplinary specialized
approach (Fig. 6). The range of management issues is diverse,
including clinical cardiovascular care, genetic evaluation and tests,
interpretation of results, conveying the information to the sur-
viving family, and managing the ongoing psychosocial wellbeing
of the families [56]. The specialized multidisciplinary cardiac
genetic clinic is a model used globally, and is dedicated to cardiac
genetics with appropriately trained staff [19,24,43,57,58]. The
multidisciplinary clinic provides expertize not only in the clinical
and genetic aspects of disease, but also in the integration of key
links with other critical members of the team in addition to the
cardiologist. These team members may include cardiac genetic
counselors, geneticists, forensic pathologists, primary care physi-
cians, nurses, clinical psychologists, and patient support groups
(Fig. 6). The role of the cardiac genetic counselor is especially
important in providing education, normalizing grief responses,
arranging genetic testing, and developing a strong bond with the
family as a key support person [59].6. Conclusions
SCD is a rare but tragic complication in a number of cardio-
vascular diseases. In the young, genetic heart diseases are an
important cause of SCD, and have major implications for surviving
at-risk family members. Therefore, a detailed evaluation of the
premorbid history and comprehensive and expert postmortem
examination are essential. In SADS cases where no cause of death
is identiﬁed at the postmortem, targeted clinical evaluation cou-
pled with molecular autopsy genetic testing in the setting of a
specialized multidisciplinary clinic are key, with the ultimate goal
to prevent future adverse clinical outcomes and SCD events in
surviving relatives.Conﬂict of interest
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